Merida launches with $121m to target autoimmune antibodies [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
The financing round was co-led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures, with participation from GV and Perceptive Xontogeny Venture (PXV) Funds. The biotech is advancing a proprietary protein engineering platform to develop fragment crystallisable (Fc)-based biologics that selectively bind and eliminate pathogenic antibodies while sparing healthy components of the immune system. Merida's therapeutics also aim to deplete the B cells responsible for producing the harmful antibodies. Merida's lead programme will focus on Graves' disease, an autoimmune condition that causes the thyroid to overproduce hormones, resulting in hyperthyroidism. The company is positioning its candidate as a more targeted alternative to antithyroid drugs (ATDs), which while being standard of care (SOC), often fail to provide adequate disease control. The company claims its approach could offer a more convenient dosing schedule and an easier route of administration compared to
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant (NASDAQ:IMVT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $28.00. They now have a "neutral" rating on the stock.MarketBeat
- Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
- Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement [Seeking Alpha]Seeking Alpha
- Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day [Yahoo! Finance]Yahoo! Finance
- Immunovant Announces Pricing of $550 Million Common Stock FinancingGlobeNewswire
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form 4
- 12/12/25 - Form 8-K
- IMVT's page on the SEC website